Announcement of J-PEM2000

Following two Pilot studies of J-PEM on troglitazone (1997�`) and losartan (1998�`), a new scheme named as "J-PEM2000" will be inaugurated from late 2000 where
1) J-PEM studies are supported and sponsored by the Japan Pharmaceutical Association (JPA), Japanese Society of Hospital Pharmacies (JSHP), and Japan Medical Association Research Institute (JMARI), as in J-PEM pilot studies,
2) two or more J-PEM studies are conducted simultaneously; in each J-PEM study, two or more new drugs with the same major indication may be monitored at the same time as "test drugs",
3) a computer software is developed and distributed to medical institutions and pharmacies where patient ID codes are registered; it will use electronic data stored in each institution and make a list of candidate patients whose ID code may be registered; it will also help data acquisition (e.g., data on co-prescribed drugs) in each institution, and
4) the protocol will be evaluated by an authentic ethics review board organized specifically for J-PEM studies.

Department of Pharmacoepidemiology, Faculty of Medicine, University of Tokyo will be responsible for J-PEM2000 as in J-PEM pilot studies. However, a new NPO (non-profitable organization) will be organized to register patient ID codes, issue questionnaires, code events reported in J-PEM.

Details will be shown in this website when more information becomes available.